US4361550A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Complement-fixing monoclonal antibody to human suppressor T cells and methods of preparing same
Assignee: Ortho Pharmaceutical Corp
•
Filing: 1979-12-04
•
Granted: 1982-11-30
•
Expires: 1999-12-04
Abstract
Abstract Hybrid cell line for production of monoclonal antibody to an antigen found on normal human suppressor T cells. The hybrid is formed by fusing splenocytes from immunized CAF 1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
Inventors
- 👤 Patrick C. Kung
- 👤 Gideon Goldstein
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 05:33
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/2803; C07K16/2815; A; A61; A61P; A61P37/00; A61K; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S530/00; Y10S530/806; Y10S530/808; Y10S530/809; Y10S530/868
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
307 words
A monoclonal antibody of class IgG produced by a hybridoma formed by fusion of cells from mouse myeloma line and spleen cells from a mouse previously immunized with human thymocytes, which antibody: (a) reacts with suppressor T cells (approximately 30 percent of normal human T cells), but with less than 2 percent of normal human bone marrow cells and not with B cells or Null cells: (b) reacts with about 80 percent of normal human thymocytes; (c) reacts with 34 percent of untreated peripheral T cells, 95 percent of peripheral T cells previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8002 and complement, and none of the peripheral T cells previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8014, and complement; and reacts with 75 percent of untreated thymocytes, 55 percent of thymocytes previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8002 and complement, 90 percent of thymocytes previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8001 and complement, and none of the thymocytes previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8014 and complement; (d) reacts with Thy 3, Thy 4, and Thy 4-6 Common Thymocyte and Thy 8 Late Thymocyte T cell ALL stages, but not with Stage I or Thy 3-4 Common Thymocyte T cell ALL stages; (e) reacts with CEM and MOLT-4 cell lines, but not with HSB-2 cell line; and (f) defines a T cell population which is lower than normal levels in primary biliary cirrhosis and multiple sclerosis, absent to lower than normal levels in hyper IgE, higher than normal levels in acute graft versus host reaction, greatly above normal levels in acute infectious mononucleosis, completely absent in myasthenia gravis, and normal levels in all stages of Hodgkins disease and psoriasis.
Claim 2
Dependent Claim
307 words
A monoclonal antibody of class IgG produced by a hybridoma formed by fusion of cells from mouse myeloma line and spleen cells from a mouse previously immunized with human thymocytes, which antibody: (a) reacts with suppressor T cells (approximately 30 percent of normal human T cells), but with less than 2 percent of normal human bone marrow cells and not with B cells or Null cells: (b) reacts with about 80 percent of normal human thymocytes; (c) reacts with 34 percent of untreated peripheral T cells, 95 percent of peripheral T cells previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8002 and complement, and none of the peripheral T cells previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8014, and complement; and reacts with 75 percent of untreated thymocytes, 55 percent of thymocytes previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8002 and complement, 90 percent of thymocytes previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8001 and complement, and none of the thymocytes previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8014 and complement; (d) reacts with Thy 3, Thy 4, and Thy 4-6 Common Thymocyte and Thy 8 Late Thymocyte T cell ALL stages, but not with Stage I or Thy 3-4 Common Thymocyte T cell ALL stages; (e) reacts with CEM and MOLT-4 cell lines, but not with HSB-2 cell line; and (f) defines a T cell population which is lower than normal levels in primary biliary cirrhosis and multiple sclerosis, absent to lower than normal levels in hyper IgE, higher than normal levels in acute graft versus host reaction, greatly above normal levels in acute infectious mononucleosis, completely absent in myasthenia gravis, and normal levels in all stages of Hodgkins disease and psoriasis.
Claim 3
Dependent Claim
13 words
The nonoclonal antibody of claim 1 which is of subclass IgG 2a .
Claim 4
Dependent Claim
32 words
The monoclonal antibody of claim 1 which is produced from a hybridoma formed by fusion of P3×63Ag8Ul myeloma cells and spleen cells from a CAF 1 mouse previously immunized with human thymocytes.
Claim 5
Dependent Claim
65 words
A monoclonal antibody of class IgG produced by a hybridoma formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with human thymocytes which reacts with suppressor T cells (approximately 30 percent of normal human T cells), but with less than 2 percent of normal human bone marrow cells and not with B cells or null cells.
Claim 6
Dependent Claim
65 words
A monoclonal antibody of class IgG produced by a hybridoma formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with human thymocytes which reacts with suppressor T cells (approximately 30 percent of normal human T cells), but with less than 2 percent of normal human bone marrow cells and not with B cells or null cells.
Claim 7
Dependent Claim
35 words
Mouse monoclonal antibody which reacts with essentially all normal human suppressor T cells but with less than 2% of normal human bone marrow cells and not with normal human peripheral B cells or null cells.
Claim 8
Dependent Claim
35 words
Mouse monoclonal antibody which reacts with essentially all normal human suppressor T cells but with less than 2% of normal human bone marrow cells and not with normal human peripheral B cells or null cells.
Claim 9
Dependent Claim
179 words
A monoclonal antibody which reacts with essentially all normal human suppressor T cells but with less than 2% of normal human bone marrow cells and not with normal human peripheral B cells or null cells, prepared by the method which comprises the steps of: (i) immunizing mice with normal human thymocytes; (ii) removing the spleens from said mice and making a suspension of the spleen cells; (iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; (iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; (v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to E rosette positive purified T cells or human thymocytes; (vi) selecting and cloning a hybridoma producing antibody which reacts with essentially all normal human suppressor T cells but with less than 2% of normal human bone marrow cells and not with normal human peripheral B cells or null cells; and (vii) recovering the antibody from the supernatant above said clones.
Claim 10
Dependent Claim
179 words
A monoclonal antibody which reacts with essentially all normal human suppressor T cells but with less than 2% of normal human bone marrow cells and not with normal human peripheral B cells or null cells, prepared by the method which comprises the steps of: (i) immunizing mice with normal human thymocytes; (ii) removing the spleens from said mice and making a suspension of the spleen cells; (iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; (iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; (v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to E rosette positive purified T cells or human thymocytes; (vi) selecting and cloning a hybridoma producing antibody which reacts with essentially all normal human suppressor T cells but with less than 2% of normal human bone marrow cells and not with normal human peripheral B cells or null cells; and (vii) recovering the antibody from the supernatant above said clones.
Claim 11
Dependent Claim
194 words
A monoclonal antibody which reacts with essentially all normal human suppressor T cells but with less than 2% of normal human bone marrow cells and not with normal human peripheral B cells or null cells prepared by the method, which comprises the steps of: (i) immunizing mice with purified human thymocytes; (ii) removing the spleens from said mice and making a suspension of the spleen cells; (iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; (iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; (v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to E rosette positive purified T cells or human thymocytes; (vi) selecting and cloning a hybridoma producing antibody which reacts with essentially all normal human suppressor T cells but with less than 2% of normal human bone marrow cells and not with normal human peripheral B cells or null cells; (vii) transferring said clones intraperitoneally into mice; and (viii) harvesting the malignant ascites or serum from said mice, which ascites or serum contains the desired antibody.
Claim 12
Dependent Claim
194 words
A monoclonal antibody which reacts with essentially all normal human suppressor T cells but with less than 2% of normal human bone marrow cells and not with normal human peripheral B cells or null cells prepared by the method, which comprises the steps of: (i) immunizing mice with purified human thymocytes; (ii) removing the spleens from said mice and making a suspension of the spleen cells; (iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; (iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; (v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to E rosette positive purified T cells or human thymocytes; (vi) selecting and cloning a hybridoma producing antibody which reacts with essentially all normal human suppressor T cells but with less than 2% of normal human bone marrow cells and not with normal human peripheral B cells or null cells; (vii) transferring said clones intraperitoneally into mice; and (viii) harvesting the malignant ascites or serum from said mice, which ascites or serum contains the desired antibody.
Claim 13
Independent Claim
60 words
A method of preparing monoclonal antibody which reacts with essentially all normal human suppressor T cells but with less than 2% of normal human bone marrow cells and not with normal human peripheral B cells or null cells, which comprises culturing the hybridoma ATCC CRL 8014 in a suitable medium and recovering the antibody from the supernatant above said hybridoma.
Claim 14
Independent Claim
60 words
A method of preparing monoclonal antibody which reacts with essentially all normal human suppressor T cells but with less than 2% of normal human bone marrow cells and not with normal human peripheral B cells or null cells, which comprises culturing the hybridoma ATCC CRL 8014 in a suitable medium and recovering the antibody from the supernatant above said hybridoma.
Claim 15
Dependent Claim
10 words
The monoclonal antibody prepared by the method of claim 8.
Claim 16
Independent Claim
62 words
A method of preparing monoclonal antibody which reacts with essentially all normal human suppressor T cells but with less than 2% of normal human bone marrow cells and not with normal human peripheral B cells or null cells, which comprises injecting into a mouse the hybridoma ATCC CRL 8014 and recovering the antibody from the malignant ascites or serum of said mouse.
Claim 17
Independent Claim
62 words
A method of preparing monoclonal antibody which reacts with essentially all normal human suppressor T cells but with less than 2% of normal human bone marrow cells and not with normal human peripheral B cells or null cells, which comprises injecting into a mouse the hybridoma ATCC CRL 8014 and recovering the antibody from the malignant ascites or serum of said mouse.
Claim 18
Dependent Claim
10 words
The monoclonal antibody prepared by the method of claim 10.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-11-29 | 1986-05-31 | 1986-11-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-11-29 | 1990-05-31 | 1990-11-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-11-29 | 1994-05-31 | 1994-11-30 | $7700.00 | Window Closed / Lapsed |